Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psychedelic drug
Biotech
Beckley Psytech psychedelic reduces depression symptoms in ph. 2
Beckley Psytech’s psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study.
James Waldron
Jul 1, 2025 8:30am
Compass' psychedelic therapy wins ph. 3, investors unimpressed
Jun 23, 2025 8:05am
Gilgamesh links psychedelic to 94% remission rate in depression
May 27, 2025 11:00am
Relmada reconsiders plans to test psilocybin for obesity
Mar 28, 2025 10:00am
Cybin psychedelic reduces depression severity after 12 months
Nov 18, 2024 12:57pm
Compass delays phase 3 psychedelic data, lays off 30% of staff
Oct 31, 2024 9:00am